Life Sciences Archive » June, 2017

Life Sciences - June, 2017

359 articles

• Product Liability Cases To Watch: Midyear Report
• Investor Says He Lost $4.8M As Shkreli Fund Failed
• Walgreen, Ocusoft Settle Eye Scrub Row
• Novartis Escapes End Payors' Gleevec Antitrust Suit
• Drug, Device Cos. Paid $8.2B To Doctors, Hospitals In 2016
• With No Bass In Drug Patent Appeal, USPTO Intervenes
• Canadian Justices Balk At 'Promise Doctrine' In Drug IP Row
• Taxation With Representation: Kirkland, WilmerHale, Latham
• NY Judge Won't Reconsider Tossing Of Pfizer's $8.3M Suit
• Opioid Users Join Fight Against Endo, Purdue, Teva
• DC Circ. Clears DEA To Block Opioid Supplier's Sales
• Health Hires: DR Welch, Greenspoon Grow Cannabis Teams
• What We're Watching In Ill.: Midyear Roundup
• SEC Asks 9th Circ. To Uphold Ex-NFLer's Negligence Verdict
• 3 Key Areas Legal Operations Teams Should Focus On
• Leegin's 10-Year Checkup: An Economist's Perspective
• Protecting And Enforcing Judgment Creditor Interests In IP
• What The Experts Said About High Court Rulings This Term
• Chamber Asks 7th Circ. Not To Revive Atty's Age Bias Suit
• Shkreli Investor Says She Felt 'Betrayed' By Bait And Switch
• J&J Says Calif. Talc Cancer Case Is Sunk By Shoddy Experts
• Allergan Settles Eye Doctor Kickback Suit For $13M
• Aveo Investors Want Class Cert. In Kidney Cancer Drug Spat
• Sandoz Wants Big Biosimilar Case Sent To District Court
• Bayer Launches $2M Suit Over Defective Sunscreen Ingredient
• St. Jude Says TC Heartland Beats Catheter Patent Suit
• Health Care Winners And Losers From The Better Care Act
• US Law Firms Face Discovery Of Foreign Clients' Records
• Leegin's 10-Year Checkup: Tips For Advising Clients On RPM
• Incentivizing Brand Pharma Cos. To Manufacture In The US
• The Future Of Law And The Demise Of The Midsize Firm
• Shkreli Atty Dubs Him 'Genius,' Denies Fraud As Trial Begins
• Pharmavite Gets OK On $1.9M Don-Doff, Wage, Break Deal
• Theranos Customers Defend Joint Venture, Battery Claims
• Amgen, Hospira Battle Over Experts Ahead Of Patent Trial
• Former Reed Smith Partner Joins Barton's Litigation Practice
• Pfizer, Direct Buyers Duel For Quick Wins In Celebrex Suit
• 6th Circ. Asked To Revive Spinal Patients' 'Disorganized' Suit
• Cravath Leads Spectranetics In €1.9B Sale To Philips
• The 10 Funniest Moments Of The Supreme Court Term
• The Most Talkative Justice Of The High Court Term
• The Cases That Got The Justices Talking
• Deals Rumor Mill: Sebia, KKR, Halliburton
• Sorrento Investor Suit Survives Dismissal Bid
• Leegin's 10-Year Checkup: No Big Changes In The Marketplace
• How Discovery Has Changed Under New Federal Rules
• Plaintiffs Bar Perspective: Beasley Allen's Andy Birchfield
• Innovating For Wise Juries: Pre-Voir Dire Questions
• Key Talc Expert Defends Cancer Link Ahead Of Calif. Trial
• Sonoma Pharma Beats Sanctions Bid Alleging Forged Letter
• CORRECTED: Pot Credit Union Can Again Seek KC Fed Account
• Fed. Circ. Vacates Invalidation Of Prenatal Testing Patent
• New FDA Chief Sheds Agency Hesitance On Drug Prices
• Shkreli Attorney Claims Bad Press Tainting Jury Pool
• Birth Control Patch Co. Shareholder Ends Stock-Drop Suit
• Gorsuch And Thomas Becoming Fast Friends At High Court
• FDA Warning Wire: Belladonna In Kids' Teething Products
• 5 High Court Concurrences That Read Like Dissents
• The Sharpest Dissents From This Supreme Court Term
• BMS, Sanofi Escape Plavix FCA Suit Under Escobar Standard
• Woman Drops Vitamin Shoppe Weight Loss Supplement Suit
• Deals Rumor Mill: Sprint, Stada, Sovcomflot
• Lincare Pays $20M To Resolve False Billing Probe
• Senate Bill May Force Rise In Suits For Opioid Funding
• Martin Shkreli Goes On Trial — What To Expect
• SEC Accuses 3 Of Illicit Ariad Trades
• Express Scripts Defends Privilege Log In Antitrust Suit
• Leegin's 10-Year Checkup: US Influence On RPM Overseas
• An Interview With Floyd Abrams
• J&J Battles Talc Cancer Expert Before First Calif. Trial
• Paul Hastings To Pay $46.5M In Deal To End ExamWorks Suit
• The Supreme Court Term By The Numbers
• The Firms That Won Big At The Supreme Court
• IP Cases Led The Pack In High Court Amicus Briefs
• Excess Insurer Says Akorn Suit Doesn't Need To Move To Ga.
• 4 Cos. Bolster IPO Pipeline With Filings Totaling $296M
• Bucking Tradition: NewLaw And The Coming Millennials
• Justices Won't Hear Sanctioned Atty's Fish Oil Class Action
• Docs Win Class Cert. In Botox Price-Inflation Action
• Pharmacist Gets 9 Years In Deadly Meningitis Outbreak
• CryoLife Claims Fraud In Battle Over $10M Merger Escrow
• Alaska Granted Intervention In DNA Testing Privacy Dispute
• Roche Defends Suit Over Alleged $89M Test Strip Scheme
• Leegin's 10-Year Checkup: State RPM Rules Vs. Federal Rule
• State AGs Responding To Trump Policies: 3 Areas To Watch
• Patent Exhaustion Ruling Will Affect Many Industries
• No Personal Jurisdiction Pass For Federal Plaintiffs
• Plaintiffs Bar Perspective: Susman Godfrey's Matthew Berry
• High Court Wants SG's Take On Vitamin C Price-Fix Dispute
• Gray Matters: We Feel, We Decide
• Fla. Gov. OKs Bill To Implement Med. Marijuana Expansion
• AbbVie Fights Hedge Funds' Bid To Return To State Court
• Top Product Liability Cases Of 2017: Midyear Report
• 8 Companies Perk Up IPO Pipeline With Deals Surpassing $1B
• Ex-BigLaw Atty Taps Proskauer For Post-Verdict Defense
• Clovis Reaches $142M Deal To Resolve Stock Drop Suit
• Pfizer Biosimilar Delayed By FDA Warning Letter
• House Debates Whether Atty 'Bad Drug' Ads Harm Patients
• Taxation With Representation: Sullivan, Vinson, Mayer
• Fed. Circ. Affirms USPTO's No-Matter-What Attys' Fees Rule
• Feds Seek 35 Years For Pharmacist In Meningitis Outbreak
• TC Heartland Considerations For Hatch-Waxman Cases
• Leegin's 10-Year Checkup: RPM Rule Breeds Inconsistency
• Farmers Awarded $218M In 1st Syngenta GMO Corn Trial
• Protect Innovation By Making FDA Compliance Admissible
• Feds, Shkreli Trade Claims Of Dubious Witness Tricks
• Inside Trader Must Shell Out $1.6M For Role In Sanofi Fraud
• AstraZeneca Affiliate Hit With $275M Merger Payment Suit
• Judge Denies Acquittal Bid In Meningitis Outbreak Case
• Pfizer Wins Interlocutory Review In Vfend Whistleblower Suit
• Patent Experts Broaden Merchant & Gould's NYC Office
• 2 Bellwethers Selected Against Lilly In Testosterone MDL
• Ind. Pharmacy Heads Charged With Selling Misdosed Drugs
• Hogan Lovells Adds Another Ex-Weil M&A Pro In Silicon Valley
• Purchasers Seek Cert. In Alere Blood Monitor Suit
• Mintz Levin Nabs Sedgwick Product Liability Litigators
• Justice Kennedy's Moderating Influence On The High Court
• Duty To Defend Doesn't Cover Counterclaims: Mass. Court
• The Shrinking Doctrine Of Specific Personal Jurisdiction
• Bard Investors Sue To Stop $24B Becton Dickinson Merger
• Justice Sotomayor On The Power Of Dissent
• Unilife, Competitor Spar Over Ch. 11 Sale Doc Access
• Forest Denied Drug Wholesalers' Profit Docs In Namenda Suit
• Altor Bioscience Suit Claims Insiders Lowballed Merger
• Impax Wants Goodwin Procter Barred In Teva Contract Fight
• Jones Day Expands IP Practice With 2 New Partners
• Inotek Investor Wants Look At Drug Test Statement Records
• A Bipartisan Call For STRONGER Patents
• Fed. Circ. Backs Gilead's Hep C Patent Win Against Idenix
• 2 Biotech Cos. Tap Follow-On Market For Nearly $500M
• Nobel Winner Attacks Sandoz Biosimilar Subpoena
• Innovating For Wise Juries: Juror-Posed Questions
• GSK Wins $235M Verdict Against Teva In Coreg Patent Fight
• News Outlet Presses Judge For Meningitis Juror Names
• FDA Says Drug Approval Scheme May Stymie Generics
• Convicted Pharmacist, Feds Fight Over Sentencing Range
• ITT Opens $1B Asbestos Coverage Trial Against 25 Insurers
• Medtronic Beats 'Free Services' Kickback FCA Suit, For Now
• Surgical Co. Investors Nab $7M Settlement In Stock-Drop Suit
• Burns & Levinson Boosts IP Bench With Technology Expert
• FDA Warning Wire: Zimmer Mea Culpa, Secret Steroids
• Salix Class Attys Seek $44.6M In Fees For $210M Settlement
• Actavis At 4: Pay-For-Delay Lawsuits Receding
• Merck Gets Out Of Patent Suit Over QR Codes
• Ionis Subsidiary Akcea Launches $125M IPO, Led By Cooley
• How 21st Century Cures Act Affects Combination Products
• Patheon Shareholders Sue To Stop $7.2B Thermo Fisher Deal
• Kirkland Steers Pamplona Capital In $5B Parexel Buyout
• Tough Times For Forum Shoppers
• FCA Lessons From A Year Of Escobar
• High Court Plavix Ruling To Shrink, Scatter Mass Torts
• Justice Sotomayor On Working A Room And The Post-Scalia Void
• Calistoga Tells Del. Justices It Earned $50M Drug Bonus
• Ex-ArthroCare CEO Invokes Honeycutt In Fraud Dismissal Bid
• Valeant Tries To Zap Claims In 4 Securities Fraud Suits
• Meal Kit Startup Blue Apron Leads Seven IPO Launches
• Ex-DOJ Consumer Protection Director Joins Venable
• Ex-Valeant CEO Blasts Drugmaker's Arbitration Bid
• Vinson & Elkins Welcomes Back Litigation Partner In Houston
• Ex-Sanofi Worker Fired For Reporting Misconduct, Suit Says
• Kimberly-Clark Can't Redo $454M Fraud Trial, Court Told
• J&J Talc Trial Derailed By High Court's Plavix Ruling
• Bard Settles 75 More Suits In Pelvic Mesh MDL
• The Evolution Of Opioid Suits And Insurance Coverage
• Ex-Insys Exec Cops To Opioid Fraud Scheme
• PerkinElmer Will Pay $1.3B For Germany's Euroimmun
• Pa. Judge Urged To Ax Defamation Suit Against Amerisource
• Pharma Cos. Tell Fed. Circ. To Reverse Durezol Decision
• 10 Problems To Avoid In Social Media Influencer Marketing
• High Court Says Plavix Suits Can't Stay In California
• FDA Will Investigate Pharma Promo Caveats, 'Overwarnings'
• 9th Circ. Won't Rethink New Falsity Standard Ruling
• Suture Co. Looks To Take Nixed Antitrust Suit To High Court
• Teva's Russian Subsidiary Pleads Guilty To FCPA Charge
• Fed. Circ. Nixes 3 Cleveland Clinic Test Patents Under Mayo
• Shkreli Wants Millions In Bail Back For Bills
• Humana Drops Pay-For-Delay Claims Against Boehringer
• Bristol-Myers Says Docs Knew Of Plavix Bleeding Risks
• Forest Says Namenda Buyers Can't Use Its Own Consultant
• The Latest On Escobar's FCA Impact
• Jurors With Strange Verdict In Meningitis Case To Be ID'ed
• One Year Later, Escobar Is Roiling FCA Landscape
• Hogan Lovells Expands To Boston, Combines With Collora
• SEC Says Maker Of Cannabis-Based Products Puffed Itself Up
• Gov't Statements Show Expansive View Of Escobar Liability
• Attys Dish On Escobar's FCA Impact One Year Later
• Ex-InterMune Exec, Friend Must Pay $746K For Insider Trading
• What DOJ Investigation Means For Generic Drug Plaintiffs
• How Science Days Are Changing Talc Litigation
• Actavis At 4: Where Pay-For-Delay Litigation Stands
• $15M Depakote Verdict A Bargaining Chip For Either Side
• FCA Decision Tracker: Continued Interpretations Of Escobar
• Tips For Complying With ABA's New Encryption Guidance
• J&J Appeals $48M Award Over Man's Severe Motrin Reaction
• State AGs Open Probe Into Opioid Drugmakers
• CytRx Floats Settlement Of Cross-Country Securities Suits
• Restless Legs Drugs Need Black Box Warnings, FDA Hears
• Ex-Pa. Doctor Sentenced To 25 Years For Running A Pill Mill
• Lilly Says Atty Fees Uncalled For After $20M Patent Loss
• Defective Bayer Warnings Led To Leg Amputation, Suit Says
• High Court's Superficial Analysis In Biosimilars Ruling
• HFF Helps Snag $75M Loan For San Francisco Tower
• Amazon Says Consumer Agreed To Its Terms In Diet Drug Row
• Derma Companies Ordered To Close Shop In FDA Row
• Pharmacist Says Feds' Misconduct Taints Meningitis Case
• 1st Circ. Clarifies Scienter Requirements
• Fed. Circ. Ruling Clears Judge To OK Mylan's Lialda Generic
• What's New About Germany's Merger Control Regime
• Rosen Firm Ends Bid To Lead NY Pharma Stock-Drop Class
• Justice Ginsburg On Oral Argument And 'Imperious' Attorneys
• Chancery Sends Innoviva Board Fight With Sarissa To Trial
• Ex-ArthroCare CFO Pleads Guilty After First Sentence Nixed
• Ranbaxy Pay-For-Delay Trial Kicks Off In Pa. Court
• Warner Chilcott Wins Transfer Of Ex-Sales Reps' Suit To NJ
• Drug Patents Fare Better At PTAB Than Others, Report Says
• Generics Makers Prevail In Menopause Drug Patent Trial
• Latham & Watkins Adds 2 Trial Pros From Kirkland & Ellis
• Cancer Drug Co. Athenex Raises $66M After IPO Prices Low
• Tenn. DAs, Addicted Baby's Guardian Sue Opioid Makers
• Rx Black Marketeer Must Repay $30M To NY Medicaid
• Firms Fight For Lead Role In Lion Biotech Investor Case
• Merck Wins PTAB Review Of Pfizer Pneumonia Vax Patent
• High Court Interprets The Biosimilars Statute — What Now?
• Theranos, Walgreens Get Blood Test Suit Largely Axed
• Texas Co. Sells Possibly Dangerous Supplement, Suit Says
• Ex-Exec, SEC Settle Suit Over Pump-And-Dump Reporting
• Alembic Pharma Gets Win In Generic Gilenya Patent Case
• Innovating For Wise Juries: Preliminary Instructions
• PTAB To Review Cialis Patent In Mylan Challenge
• FDA Warning Wire: Bad Drug Info, Lax Contact Lens Records
• McKesson, CVS Look To Toss, Pause Cherokee Opioid Suit
• Painkiller Patents Too Vague To Stand, Fed. Circ. Says
• Microsoft Ruling Backs Cymbalta Suit, Lilly Tells 9th Circ.
• Ex-MLB Player Fights Insider Trading Verdict
• Witness In $25M Med Device Trial Gets 15 Months For Lying
• Due Diligence From The Lateral Partner's Perspective
• Artery Imaging Device Co. Hit With Suit Over $65M IPO
• Patient In First Xarelto Bellwether Wants New Trial
• FDA Lines Up Forum On Abuse-Deterrent Opioids
• FDA Rejects Coherus Application For Neulasta Biosimilar
• Ga. Pharmacy Pays $2M To Resolve False Claims Act Probe
• Ex-Pot Co. Owner Seeks To Shift SEC Fraud Claims Onto Atty
• South Africa Probes Roche, Pfizer, Aspen Over Drug Pricing
• An Interview With Ex-USPTO Director Todd Dickinson: Part 2
• Lateral Partner Due Diligence: Where Should A Firm Begin?
• Justice Ginsburg On Diversity And Persuading Her Colleagues
• Talc Is Clearly Toxic, Expert Says In J&J Cancer Trial
• 6 Key Takeaways From High Court's Big Biosimilar Ruling
• Deals Rumor Mill: Toshiba, Bayer, Lotte
• Feds Seek $132.8M From Convicted Meningitis Fraudster
• Detroit Must Refund Income Tax To Passive Holding Company
• Bayer, Janssen Win 2nd Xarelto Bellwether Trial
• Lab Supplier's $6.4B Sale Has Investors In Dark, Suit Says
• Pfizer Combo Drug Gets New Exclusivity After Ferring Win
• An Interview With Ex-USPTO Director Todd Dickinson: Part 1
• Mistrial Declared In First Androgel Bellwether
• High Court Boosts Biosimilars By Allowing Early Notice
• 6th Circ. Affirms Ex-Atty's Lengthy Sentence In 2nd Appeal
• J&J Targeted Minorities With Deadly Talc, Jury Told
• GE Owes $131M Damages For Anesthesia Monopoly, Cos. Say
• Contention Gives Way To Compromise In Fla. Special Session
• Coherus Assails Amgen's Neulasta Biosimilar Suit
• Product Liability Regulation & Legislation: Midyear Report
• Bayer, Janssen Say Blood Thinner Warning Claim Preempted
• Philly Jury Clears J&J In Latest Pelvic Mesh Case
• Walgreens, McKesson Look To Block Cherokee Opioid Suit
• Native American Cases To Watch In The 2nd Half Of 2017
• EU Approves J&J's $30B Actelion Buy, With Conditions
• TC Heartland & Hatch-Waxman: The Sky's Not Falling
• Abbott Labs Hit With $15M Verdict In Depakote Trial
• Keys To Successful Swear-Behind Attempts Before PTAB
• FDA Asks Endo To Remove Opana ER, Citing Opioid Crisis
• 6 Highlights From Busy Health Policy Day On Capitol Hill
• Royalty Biz Seeks Toss Of Hedge Fund's Bid For Board Seats
• Northwestern Doc Says AbbVie's Androgel Has Heart Risks
• FTC Fights Watson's Bid To Block Lidoderm Antitrust Suit
• EU High Court Nixes German Co.'s Glucose Health Claims
• Essure Patients Say Suit Against Bayer Belongs In State Court
• Kyle Bass Gets Diprivan Patent Claims Nixed In PTAB Review
• 'Phantom Pain' Device Maker Misled Investors, Suit Says
• MoFo Nabs Wilson Sonsini Life Sciences Atty In SF
• Valeant Sells Aussie Pharma Biz To PE Shops For $930M
• NJ Drugmaker Accuses Ex-Partner Co. Of Defamation
• Foley & Lardner Adds Ex-Ropes & Gray Atty To NY Office
• Fla. Legislature Reaches Deal To Address Medical Marijuana
• Robbins Geller To Lead Investor Suit Over Sequenom Deal
• Depakote Birth Defect Trial Goes To Jury With Plea For $40M
• J&J Reaches Deal In 'Natural' Sunscreen Suit
• Stryker Unit Says Biomet Trade Secret Suit Should Proceed
• Mylan, Others Rigged Generic Drug Prices, Suits Say
• Sessions Stops 3rd-Party Donation Settlements
• Insurer Tells 3rd Circ. That Carriers Liable In $9M Drug Theft
• Deals Rumor Mill: Allianz, Lotte Group, Alitalia
• La. Not Immune From Flonase Class Settlement, Says GSK
• Stockholder Demands Look At Ambry Genetics' Books
• Device Maker, UPenn Sued For Heart Surgery Infection
• Roche Faces Stock Drop Suit Over Cancer Drug Results
• Plaintiffs Bar Perspective: Motley Rice's Donald Migliori
• Innovating For Wise Juries: Setting Trial Time Limits
• Drug Co. Sellers Ask Nix Of Fraud Claims In $2B Teva Suit
• Carlyle, GTCR Ink $21.75-Per-Share Buyout Of AMRI
• Bayer Asks For Block Of CAP IM Anti-Tick Dog Treatment
• Big Business Lobby Tries To Hobble Litigation Finance, Again
• Novartis Wins $2M Over Ex-Employee's Tossed Bias Suit
• McCarter & English Adds 2 Product Liability Litigators
• Halt Medical Cleared For Ch. 11 Asset Sale To DIP Lender
• FDA Warning Wire: Big Generic-Drug Cos., OTC Biz Scolded
• Ex-FDA Head Says AbbVie Promoted Off-Label Androgel Use
• 3rd Circ. Could Upset Class Pacts In Flonase Antitrust Row
• Ex-Insys Manager Will Plead Guilty To Insurance Fraud
• Olympus Settles Pa. Suit Over FDA-Flagged Surgical Tool
• Amgen Patents Don't Advance Drug Science, Fed. Circ. Told
• Deals Rumor Mill: Valeant, Snap, WuXi Biologics
• FTC, AbbVie Seek Quick Wins In Androgel Antitrust Suit
• Sloan Kettering Secures Sanctions In Drug IP Case
• Lessons From Risk Minimization FCA Cases Post-Escobar
• After The BNSF Decision, There's No Place Like 'At Home'
• AbbVie Confronts 1st Bellwether In Androgel MDL
• Colgate Seeks Stay Of 2 Cases Until FDA Defines 'Natural'
• Investor's Smear-And-Short Judgment, Case Tossed In Del.
• Cancer-Focused Biotech Co. Athenex Launches $72M IPO
• Express Scripts, CVS Face ERISA Suit Over EpiPen Costs
• Corp. Attys Back Drug Co. In FTC Privilege Fight At DC Circ.
• FDA, Amgen Shelve Sensipar Exclusivity Case
• Express Scripts Must Face Antitrust Suit, NY Pharmacy Says
• Akorn Says Excess Insurer Sued Too Soon Over $20M Verdict
• Enzo, Yale Push To Revive $61M Patent Award Over DNA Tech
• Lincare FCA Settlement Awaits DOJ Approval
• Vapor Smoke And Mirrors: The Future Of E-Cigarettes
• Congressional Forecast: June
• Diabetes Test Supplier Wants Abbott's Protected Emails
• 6 Suits Say Mylan, Others Rigged Generic Drug Prices
• Teva To Face Cancer Liability Claims In 9th Circ. Reversal
• Meal Kit Startup Blue Apron Leads 7 New IPO Filings
• Drug Return Co. Wants Acquittal, New Trial In $116M Fraud
• Health Hires: Epstein, Greenberg, McDermott, Polsinelli
• 3rd Circ. Upholds Pfizer Win In Zoloft Birth Defect MDL
• Pharma Co., Ex-CEO Fight Over Disqualifying Counsel
• Stanford, ThermoLife Seek To Slash Fee Award In IP Suit
• German Co. Seeks Attys' Fees In $20M Cialis IP Trial
• Patterson Thuente Nabs Patent Prosecutor For Sciences Team
• Feds Say Shkreli's Past Fund Failures Relevant To Trial
• Judge OKs DS Heathcare's $2.1M Stock Drop Settlement
• SEC's Win In NFLer Stock Scam Suit Improper, Atty Says
• CryoLife Trying To Swipe $10M Merger Escrow, Investors Say
• Dr. Spared Fine Over Accountant's Stock Sale Tax Gaffes
• NJ Stryker Hip Implant Suits Consolidated In State Court
• Deals Rumor Mill: Stitch Fix, SoftBank, Tesaro
• JPML Won't Combine Suits Over Memory Booster Prevagen
• Actos Buyers Fight To Preserve Market-Exclusivity Suit
• No Basis For FTC Lidoderm Pay-For-Delay Suit, Watson Says
• J&J Seeks Pause In 'Natural' Baby Wash Suit
• Ohio Sues Cephalon, Purdue, Endo Over Opioid Crisis
• B. Braun's Generic Infringes 2 Painkiller Patents, Rival Says
• Bard Hit With Antitrust Suit Over Alleged Catheter Tying
• No Tax Relief For New Mexico's Marijuana Businesses
• Janssen Takes Another 'Patent Dance' Step In Remicade Case
• Levi & Korsinsky Will Lead Insys Shareholder Suit
• Talc Talk: 1 Of These Verdicts Is Not Like The Others